Medicine

Molecular profiling of BRAF-V600E-mutant metastatic intestines cancer in the phase\u00e2 $ 3 FLARE CRC test

.Contending rate of interests.S.K.: Stock and Other Possession Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or even Advisory Role: AbbVie, Amal Therapeutics, AstraZeneca/MedImmune, Bayer Health And Wellness, Bicara Therapies, Boehringer Ingelheim, Boston Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Effort BioMedicines, Blaze Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Health Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Music Drugs, Lilly, Lutris, Merck, Mirati Therapies, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Analysis Financing: Amgen (Inst), Assortment BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: In The Past Pfizer. Sell as well as Various Other Ownership Interests: Pfizer. J.P.: Job: Previously Pfizer. Stock and Other Possession Stakes: Pfizer. F.C.: Consulting or Advisory Task: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Research Financing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Role: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Study Funding: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Function: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Drug, Terumo. H.S.W.: Consulting or even Advisory Job: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapeutics, Erytech Pharma, Incyte, Merck KGaA, Oaktree Lifestyle Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, Shire, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Analysis Funding: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Drug, Sumitomo Corp., Takeda. Research Backing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Pharmaceutical (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Work: Pfizer. Sell and also Other Ownership Interests: Pfizer. X.Z.: Job: Pfizer. Share and Other Possession Stakes: Pfizer. Patents, Aristocracies, Various Other Copyright: Johns Hopkins University. P.H.: Employment: Pfizer. Supply as well as Various Other Possession Interests: Pfizer. T.X.: Job: Pfizer. Sell and Other Ownership Claims: Pfizer. R.Y.: Consulting or even Advisory Role: Collection BioPharma/Pfizer, Mirati Therapies, Zai Laboratory, Amgen. Study Backing: Collection BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Rehab (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or even Advisory Duty: Assortment BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Rehabs, MSD, NeoPhore, Novartis, Ona Therapies, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Rehab, Seagen Inc., Servier, Taiho Drug, Tessa Rehab, TheraMyc. Other Partnership: Amgen, Variety Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Analysis UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Converse el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health KGaA, MJH Lifestyle Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapies, PeerView Principle for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Learning Information, Sanofi-Aventis, Servier, Taiho Drug.